Search results
Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
Reuters via Yahoo Finance· 11 months agoJohnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster...
Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?
Motley Fool· 2 years agoIf a company is able to secure approval for a drug treatment and swipe market share from other...
Stelara biosimilar from Alvotech, Teva approved by FDA
BioPharma Dive via Yahoo Finance· 1 week agoDive Brief: Alvotech and Teva on Tuesday won Food and Drug Administration approval for Selarsdi, the...
Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Reuters via Yahoo News· 11 months ago(Reuters) -Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of...
Bellwether Health Giant J&J Skids As Psoriasis Blockbuster Drags Top Line
Investor's Business Daily· 1 week agoJohnson & Johnson stock skidded early Tuesday after light sales of blockbuster psoriasis treatment...
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
Zacks via Yahoo Finance· 1 year agoIn J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara...
J&J's medical device sales fall short, cancer drugs seen growing
Reuters via Yahoo Finance· 2 weeks ago(Reuters) -Johnson & Johnson's first-quarter revenue missed Wall Street estimates for medical...
Are your prescription drugs affordable? Colorado board wants feedback on these 2
KDVR Denver via Yahoo News· 1 week agoDENVER (KDVR) — A Colorado board continues reviewing the cost of prescription drugs, and public...
Johnson & Johnson forecasts as much as 6% sales growth in 2024
Reuters via Yahoo News· 5 months ago(Reuters) -Johnson & Johnson on Tuesday forecast revenue growth of 5-6% for 2024, its first full...
J&J sues Amgen over plan to sell drug similar to blockbuster Stelara
Reuters via Yahoo Finance· 1 year ago(Reuters) -Johnson & Johnson's Janssen unit has sued Amgen Inc over its plan to market a drug for...